Hikma Pharmaceuticals (HIK) Stock Forecast & Price Target

→ Can't believe it's happening again (From Manward Press) (Ad)

GBX 1,778.66

-28.34 (-1.57%)

(As of 04:40 PM ET)

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

Hikma Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Analysts' Consensus Price Target

GBX 2,068.75

High Forecast	GBX 2,150
Average Forecast	GBX 2,068.75
Low Forecast	GBX 2,000

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	GBX 2,068.75	GBX 2,018.75	GBX 1,972.50	GBX 1,915

Get Hikma Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

HIK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HIK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hikma Pharmaceuticals Stock vs. The Competition

Type	Hikma Pharmaceuticals	Medical Companies
Consensus Rating Score	2.50	2.68
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Neutral News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
4/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	GBX 2,000	+8.75%
2/26/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold	GBX 1,960 ➝ GBX 2,000	+0.03%
11/13/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform	GBX 2,150	+22.16%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
10/3/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
5/22/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	GBX 2,080 ➝ GBX 2,125	+15.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:40 PM ET.

HIK Price Target - Frequently Asked Questions

What is Hikma Pharmaceuticals's consensus rating and price target?: According to the issued ratings of 6 analysts in the last year, the consensus rating for Hikma Pharmaceuticals stock is Moderate Buy based on the current 3 hold ratings and 3 buy ratings for HIK. The average twelve-month price prediction for Hikma Pharmaceuticals is GBX 2,068.75 with a high price target of GBX 2,150 and a low price target of GBX 2,000. Learn more on HIK's analyst rating history.
Do Wall Street analysts like Hikma Pharmaceuticals more than its competitors?: Analysts like Hikma Pharmaceuticals less than other Medical companies. The consensus rating score for Hikma Pharmaceuticals is 2.50 while the average consensus rating score for medical companies is 2.68. Learn more on how HIK compares to other companies.
Does Hikma Pharmaceuticals's stock price have much upside?: According to analysts, Hikma Pharmaceuticals's stock has a predicted upside of 11.24% based on their 12-month stock forecasts.

What analysts cover Hikma Pharmaceuticals?: Hikma Pharmaceuticals has been rated by Barclays, and Berenberg Bank in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (LON:HIK) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hikma Pharmaceuticals (HIK) Stock Forecast & Price Target

Hikma Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

HIK Analyst Ratings By Month

HIK Price Targets by Month

Hikma Pharmaceuticals Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

HIK Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info